FYERS
Home
/
Stocks
/
Profit Loss
/
Medicamen Biotech Profit & Loss

Medicamen Biotech Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021Dec 2020Sep 2020Jun 2020Mar 2020Dec 2019Sep 2019Jun 2019Mar 2019
₹48 Cr₹61 Cr₹47 Cr₹47 Cr₹43 Cr₹30 Cr₹45 Cr₹45 Cr₹43 Cr₹47 Cr₹47 Cr₹44 Cr₹42 Cr₹39 Cr₹36 Cr₹34 Cr₹33 Cr₹23 Cr₹33 Cr₹33 Cr₹28 Cr₹21 Cr₹33 Cr₹31 Cr₹28 Cr₹24 Cr₹35 Cr₹36 Cr₹31 Cr₹24 Cr
₹86 L₹2 Cr₹54 L₹37 L₹47 L₹5 Cr₹14 L₹29 L₹59 L₹57 L₹83 L₹55 L₹38 L₹35 L₹63 L₹53 L₹96 L₹34 L₹83 L₹48 L₹8 L₹54 L₹10,000₹13 L₹8 L₹1 Cr₹45 L₹35 L₹4 L₹7 L
₹49 Cr₹62 Cr₹47 Cr₹48 Cr₹44 Cr₹35 Cr₹45 Cr₹45 Cr₹44 Cr₹48 Cr₹47 Cr₹44 Cr₹42 Cr₹39 Cr₹36 Cr₹34 Cr₹34 Cr₹23 Cr₹33 Cr₹33 Cr₹28 Cr₹22 Cr₹33 Cr₹31 Cr₹28 Cr₹25 Cr₹36 Cr₹36 Cr₹31 Cr₹24 Cr
₹45 Cr₹57 Cr₹44 Cr₹44 Cr₹40 Cr₹32 Cr₹41 Cr₹42 Cr₹41 Cr₹43 Cr₹43 Cr₹41 Cr₹37 Cr₹34 Cr₹31 Cr₹29 Cr₹29 Cr₹19 Cr₹28 Cr₹28 Cr₹23 Cr₹17 Cr₹28 Cr₹26 Cr₹24 Cr₹21 Cr₹31 Cr₹30 Cr₹27 Cr₹20 Cr
₹5 Cr₹7 Cr₹5 Cr₹6 Cr₹5 Cr₹4 Cr₹7 Cr₹6 Cr₹4 Cr₹6 Cr₹6 Cr₹5 Cr₹7 Cr₹7 Cr₹7 Cr₹6 Cr₹7 Cr₹5 Cr₹7 Cr₹7 Cr₹6 Cr₹5 Cr₹5 Cr₹6 Cr₹4 Cr₹4 Cr₹6 Cr₹6 Cr₹5 Cr₹4 Cr
₹83 L₹38 L₹97 L₹99 L₹1 Cr₹65 L₹76 L₹1 Cr₹71 L₹2 Cr₹65 L₹91 L₹96 L₹86 L₹68 L₹62 L₹77 L₹56 L₹49 L₹30 L₹4 L₹36 L₹9 L₹38 L₹24 L₹0₹19 L₹21 L₹16 L₹20 L
₹3 Cr₹5 Cr₹2 Cr₹3 Cr₹2 Cr₹2 Cr₹4 Cr₹2 Cr₹2 Cr₹3 Cr₹3 Cr₹2 Cr₹5 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr₹3 Cr₹5 Cr₹5 Cr₹5 Cr₹4 Cr₹4 Cr₹5 Cr₹3 Cr₹3 Cr₹5 Cr₹5 Cr₹4 Cr₹4 Cr
₹2 Cr₹4 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹3 Cr₹91 L₹80 L₹2 Cr₹2 Cr₹1 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr₹3 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr₹3 Cr₹3 Cr₹2 Cr₹2 Cr₹4 Cr₹4 Cr₹3 Cr₹2 Cr

Share Price Live Stats

Open (₹)262.00
Volume (₹)30,221.00
High (₹)273.00
Upper Circuit311.25
Low (₹)260.65
Lower Circuit207.55
Prev Close259.40
52W High (₹)447.65
Price264.00
52W Low (₹)212.40

Share Market Cap & Key Ratios Overview

M.Cap (₹)353.11 Cr
Div. Yield (%)0.38
PE Ratio32.61
Debt to Equity0.16
Price to Book2.97
Book Value162.23
EPS (TTM)7.98
Face Value10.00
ROE (%)3.23

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
MEDICAMEQNSE
LTP
1W Low
1W High
Market cap (₹)
1905.5-14.5 (-0.76%)
1902
1984.80
4,56,833Cr
9218.5-20.5 (-0.22%)
9087
9467
2,45,426Cr
4895.5-154.5 (-3.06%)
4885
5066
1,87,320Cr
1133.8-57.2 (-4.80%)
1125.10
1187
1,13,217Cr
1391.6-31.9 (-2.24%)
1376.70
1426.10
1,12,212Cr
1853.5-85 (-4.38%)
1811.70
1949
1,01,155Cr
2126.5-45 (-2.07%)
2118.10
2192
97,626Cr
2350.8-32.1 (-1.35%)
2341.20
2419.20
96,859Cr
1164.3-13.7 (-1.16%)
1154.40
1179.90
96,406Cr
1655.4+10.1 (0.61%)
1622.60
1717
93,614Cr
264+15.12 (6.08%)
246
279
353Cr

Key Highlights of Medicamen Biotech Ltd’s P&L

In 2025-03-31, Medicamen Biotech Ltd reported total revenue of ₹168.8Cr, compared with ₹181.63Cr in 2024-03-31, reflecting Medicamen Biotech Ltd turnover.

Depreciation was ₹7.07Cr and finance costs were ₹3.72Cr in 2025-03-31

Profit Before Tax (PBT) has been ₹9.88Cr in 2025-03-31 as compared to ₹13.08Cr in 2024-03-31.

Net Profit (PAT) was ₹6.56Cr in 2025-03-31 compared with ₹9.49Cr in 2024-03-31.

Earnings per share (EPS) were ₹5.16 in 2025-03-31, compared with ₹7.47 in 2024-03-31.